Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Substitutions at NS3 Residue 155, 156, or 168 of Hepatitis C Virus Genotypes 2 to 6 Induce Complex Patterns of Protease Inhibitor Resistance.

Antimicrobial agents and chemotherapy - 1 Dec 2015

Jensen Sanne B, Serre Stéphanie B N, Humes Daryl G, Ramirez Santseharay, Li Yi-Ping, Bukh Jens, Gottwein Judith M

Abstract excerpt

Various protease inhibitors (PIs) currently are becoming available for treatment of hepatitis C virus (HCV). For genotype 1, substitutions at NS3 protease positions 155, 156, and 168 are the main determinants of PI resistance. For other genotypes, similar substitutions were selected during PI treatment but were not characterized systematically. To elucidate the impact of key PI resistance substitutions on...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amides
Share to Carbamates

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclopropanes

Share to Oligopeptides

Share to Protease Inhibitors

Share to Quinoxalines

Share to Sulfonamides

Share to Viral Nonstructural Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 26392503
DOI: 10.1128/AAC.01953-15
PMCID: PMC4649233

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Substitutions at NS3 Residue 155, 156, or 168 of Hepatitis C Virus Genotypes 2 to 6 Induce Complex Patterns of Protease Inhibitor Resistance.PMID 26392503Read ↗

Hepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants: <i>In Vitro</i> Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life CycleSemantic proximity Read ↗

Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape VariantsSemantic proximity Read ↗

Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor. Reduced RNA replication fitness and partial rescue by second-site mutations.Semantic proximity Read ↗

Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191).Semantic proximity Read ↗

The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease InhibitorsSemantic proximity Read ↗

Resistance-associated mutations to HCV protease inhibitors naturally pre-existed in HIV/HCV coinfected, treatment-naïve patients.Semantic proximity Read ↗

HCV Genotype 6a Escape From and Resistance to Velpatasvir, Pibrentasvir, and Sofosbuvir in Robust Infectious Cell Culture Models.Semantic proximity Read ↗

NS3 protease polymorphisms and genetic barrier to drug resistance of distinct hepatitis C virus genotypes from worldwide treatment-naïve subjects.Semantic proximity Read ↗

In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir.Semantic proximity Read ↗

Hepatitis C virus resistance to protease inhibitors.Semantic proximity Read ↗

Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patientsSemantic proximity Read ↗

Molecular Mechanism of Resistance in a Clinically Significant Double-Mutant Variant of HCV NS3/4A Protease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.